^
Association details:
| Biomarker: | NRAS mutation |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Eylea (aflibercept intravitreal) (VEGF-A inhibitor, PIGF inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Aflibercept-LV5FU2 as first-line treatment of non-resectable metastatic colorectal cancers: Results of the FOLFA randomized phase II trial.
Published date:
05/26/2022
Excerpt:
117 patients (pts) were included, 59 in arm A (5FU-aflibercept), 58 in arm B (5FU alone), of median age 81 years (range 67-91; > 75 years: 81%). RAS/BRAF status (available in 112 pts [96%]) was mutated in 49% and 7%, respectively. The 6-month PFS was 54% in both arms (same 90% CI 42-65). The disease control rate was 83% in arm A and 87% in arm B. The median OS was 21.8 months in arm A and 25.1 months in arm B. FOLFA trial meets is primary endpoint with 53.6% of 6-month PFS with LV5FU2-aflibercept. Nevertheless, as compared with LV5FU2 alone we observed no increase in PFS or OS and more toxicities.
Secondary therapy:
LV5FU2
Trial ID:
